Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.39 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.39 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16510003 | 1.00 | SMN1; SMN2 (0.47) | SMN1; SMN2CA2HPGDPRKCDCAMK2B | |
| SCHEMBL14129503 | 0.99 | SMN1; SMN2 (0.45) | SMN1; SMN2CA2HPGDPRKCDCAMK2B | |
| SCHEMBL14330850 | 0.95 | SMN1; SMN2 (0.52) | SMN1; SMN2CA2HPGDBRD4NPC1 | |
| SCHEMBL13307352 | 0.94 | SMN1; SMN2 (0.50) | SMN1; SMN2CA2HPGDBRD4NPC1 | |
| SCHEMBL13307358 | 0.91 | SMN1; SMN2 (0.47) | SMN1; SMN2CA2HPGDNPC1RAB9A | |
| SCHEMBL20919156 | 0.91 | SMN1; SMN2 (0.50) | SMN1; SMN2CA2HPGDPRKCDCAMK2B | |
| SCHEMBL14129352 | 0.89 | BRD4 (0.47) | SMN1; SMN2HPGDBRD4NPC1RAB9A | |
| SCHEMBL10191049 | 0.86 | BRD4 (0.45) | BRD4NPC1RAB9AMEN1KMT2A | |
| SCHEMBL14129350 | 0.86 | SMN1; SMN2 (0.44) | SMN1; SMN2CA2HPGDBRD4NPC1 | |
| SCHEMBL15076060 | 0.85 | BRD4 (0.45) | HDAC3HDAC1BRD4NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3697404-B1 | COMPOSITIONS AND METHODS FOR BROAD-SPECTRUM ANTIVIRAL THERAPY | VERSITECH LTD (HK) | 2025-03-26 | — | — | EP | disclosed |
| US-12213955-B2 | Compositions and methods for broad-spectrum antiviral therapy | VERSITECH LIMITED (CN) | 2025-02-04 | — | — | US | disclosed |
| CN-111886008-B | Compositions and methods for anti-MERS-coronavirus therapy | 港大科桥有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-111886008-A | Compositions and methods for broad spectrum antiviral therapy | 阿瓦隆黄病毒治疗(香港)有限公司 | 2020-11-03 | — | — | CN | disclosed |
| US-20200338032-A1 | COMPOSITIONS AND METHODS FOR BROAD-SPECTRUM ANTIVIRAL THERAPY | VERSITECH LIMITED (CN) | 2020-10-29 | — | — | US | disclosed |
| US-20080181847-A1 | Targeted Imaging and/or Therapy Using the Staudinger Ligation | KONINKLIJKE PHILIPS ELECTRONICS, N.V. (NL) | 2008-07-31 | — | — | US | disclosed |
| US-20080181847-A1 | Targeted Imaging and/or Therapy Using the Staudinger Ligation | KONINKLIJKE PHILIPS ELECTRONICS, N.V. (NL) | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080181847-A1 | Targeted Imaging and/or Therapy Using the Staudinger Ligation | BTD, HLCS, BOLA2; BOLA2B | SMN1; SMN2 2929/4885CA2 4599/4885HPGD 2259/4885 |
| US-20200338032-A1 | COMPOSITIONS AND METHODS FOR BROAD-SPECTRUM ANTIVIRAL THERAPY | MAVS, RARB, RARG | SMN1; SMN2 4086/4885CA2 4852/4885HPGD 4038/4885 |
| US-12213955-B2 | Compositions and methods for broad-spectrum antiviral therapy | MAVS, RARB, RARG | SMN1; SMN2 4099/4885CA2 4856/4885HPGD 3998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.